Arie Belldegrun - Jun 10, 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Director
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Jun 10, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/13/2022, 09:13 PM
Previous filing: Jun 10, 2022
Next filing: Jun 29, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Award	$0	+70.9K	+378.43%	$0.00	89.7K	Jun 10, 2022	Direct	F1
holding	DNA	Class A Common Stock						500K	Jun 10, 2022	By Bellco Legacy LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Stock Option	Award	$0	+109K		$0.00	109K	Jun 10, 2022	Class A Common Stock	109K	$2.82	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date.
F2	Bellco Legacy LLC is owned and managed by trusts controlled by the Reporting Person and Rebecka Belldegrun.
F3	In accordance with the Non-Employee Director Compensation Policy of the Issuer, the Black-Scholes value of the option award as of the grant date is $200,000.